DRUG DEVELOPMENT

Applications of Biomolecular Interaction Analysis in drug development

Biomolecular Interaction Analysis (BIA) based on the physical principle of surface plasmon resonance (SPR) is utilised in nearly all phases of drug development. Thus, BIA is a valuable tool for getting high quality data of the binding of LMW compounds to a protein on the step of target identification, screening of potential hit molecules and candidate drug selection in the preclinical and clinical development.

BIA covers a broad range of applications including

target identification/validation
hit/lead identification/selection
secondary screenings
lead optimisation/characterisation
early ADME assays
candidate drug selection/characterisation
immunogenicity studies

Assay development and functional binding assays for compound characterisation are the most commonly used applications of BIA in drug development.

Benefit from the advantage of SPR technology as label-free analysis in real time and yield highly reproducible kinetic data with low sample consumption.